[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
Gan To Kagaku Ryoho
; 39(11): 1608-12, 2012 Nov.
Article
em Ja
| MEDLINE
| ID: mdl-23152011
ABSTRACT
Despite extensive progress in basic and translational research, there are few clinically relevant predictive biomarkers for response to conventional chemotherapeutic agents(irinotecan, platinum drugs, taxanes)that can guide in the selection of an optimal chemotherapy regimen. Molecular-targeted drugs are designed to act on specific mutated/overexpressed molecules of cancer cells, and the application of predictive biomarkers for response to these drugs has been well explored. Conventional cytotoxic drugs also target-specific cellular molecules. They act on nucleic acid, enzymes related to nucleic acid metabolism, or microtubules. Now we can develop new predictive biomarkers for conventional chemotherapy using recent molecular biology techniques and molecular epidemiological studies. In this review, we summarize the investigation and application of predictive biomarkers for response to cytotoxic drugs. We focus on UDP-glucuronosyltransferase 1A1(UGT1A1), breast cancer resistance protein(BCRP), and DNA topoisomerase I (Top1)for predictive biomarkers to irinotecan therapy; glutathione S-transferase P1(GSTP1), excision repair cross-complementing 1/2(ERCC1/2), and breast cancer susceptibility gene 1/2(BRCA1/2)for response to platinum drugs; and b-tubulin, GSTP1, and thioredoxin for taxane therapy.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Camptotecina
/
Biomarcadores Tumorais
/
Compostos de Platina
/
Taxoides
/
Neoplasias
/
Antineoplásicos
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Limite:
Humans
Idioma:
Ja
Revista:
Gan To Kagaku Ryoho
Ano de publicação:
2012
Tipo de documento:
Article
País de afiliação:
Japão